Shopping Cart 0
Cart Subtotal
AED 0

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 25690

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 38535
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Integrin Alpha V-Pipeline Review, H2 2018'; Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) pipeline Target constitutes close to 31 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Integrin alpha-V is a protein encoded by the ITGAV gene. Alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin regulate angiogenesis and cancer progression.

The report 'Integrin Alpha V-Pipeline Review, H2 2018' outlays comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 6 and 18 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively.

Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Respiratory, Infectious Disease, Cardiovascular and Immunology which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Persistent Corneal Epithelial Defects, Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Liver Fibrosis, Metastatic Melanoma, Pancreatic Cancer, Wounds, Age Related Macular Degeneration, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Foot Ulcers, Diabetic Macular Edema, Genital Warts (Condylomata Acuminata), Malabsorption Syndrome, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Rheumatoid Arthritis, Sepsis and Venous Leg Ulcers (Crural Ulcer).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

- The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Overview

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Companies Involved in Therapeutics Development

Biogen Inc

BioMAS Ltd

BrightGene Bio-Medical Technology Co Ltd

Factor Therapeutics Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Morphic Therapeutic Inc

Pliant Therapeutics Inc

SciFluor Life Sciences LLC

Tasly Pharmaceutical Group Co Ltd

Vascular Pharmaceuticals Inc

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Drug Profiles

264-RAD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abituzumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Integrin Inhibit Alpha V and Beta 6 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAT-2094-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BG-00011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGC-0222-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-16Y-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cilengitide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CWHM-12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize Integrin Alpha V Beta 3 and Integrin Alpha 5 Beta 1 for Rheumatoid Arthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-0429-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSP-68-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOD-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCU-200-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Metastatic Melanoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLN-74809-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proagio-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSF-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-0166-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ITGAV and ITGB1 for Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ITGAV and ITGB6 for Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha V for Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha V for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetraiodothyroacetic acid-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-003-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-2690B-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Dormant Products

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Discontinued Products

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Product Development Milestones

Featured News & Press Releases

Oct 09, 2018: Merck KGaA to announce data of Abituzumab at ESMO 2018 Congress

Oct 04, 2018: Factor Therapeutics announce treatment completion marks milestone in Phase 2 clinical trial

Oct 02, 2018: Factor Therapeutics provides shareholder update Q3 2018

Sep 05, 2018: Factor Therapeutics announced phase 2 clinical trial for venous leg ulcers nears completion

Aug 06, 2018: Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis

Jul 19, 2018: Cassiopea announces top line positive proof of concept phase II results for CB-06-02 immune modulator in treating genital warts

Jul 16, 2018: Factor Therapeutics: Recruitment Completed in VF00102

Jun 26, 2018: VF00102 CLINICAL TRIAL UPDATE: Screening Closed to New Patients as Recruitment Nears Completion

Jun 14, 2018: Factor Therapeutics: VF001002 Clinical Trial Update

May 14, 2018: Factor Therapeutics announces its VF00102 Clinical Trial Recruitment Enters Final Phase

Apr 10, 2018: Factor Therapeutics Provides Update on VF00102 Clinical Trial

Dec 18, 2017: SciFluor announces positive top-line results of phase 1/2 study of SF0166 eye drops to treat wet age-related macular degeneration

Dec 12, 2017: SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases

Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts

Nov 29, 2017: Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Biogen Inc, H2 2018

Pipeline by BioMAS Ltd, H2 2018

Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2018

Pipeline by Factor Therapeutics Ltd, H2 2018

Pipeline by MedImmune LLC, H2 2018

Pipeline by Merck & Co Inc, H2 2018

Pipeline by Merck KGaA, H2 2018

Pipeline by Morphic Therapeutic Inc, H2 2018

Pipeline by Pliant Therapeutics Inc, H2 2018

Pipeline by SciFluor Life Sciences LLC, H2 2018

Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018

Pipeline by Vascular Pharmaceuticals Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Dormant Products, H2 2018 (Contd..3), H2 2018

Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Therapeutic Products under Development, Key Players in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Therapeutics, Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Pipeline Overview, Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Pipeline, Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Pipeline Assessment


Companies

Biogen Inc

BioMAS Ltd

BrightGene Bio-Medical Technology Co Ltd

Factor Therapeutics Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Morphic Therapeutic Inc

Pliant Therapeutics Inc

SciFluor Life Sciences LLC

Tasly Pharmaceutical Group Co Ltd

Vascular Pharmaceuticals Inc

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Integrin Alpha V-Pipeline Review, H2 2018'; Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) pipeline Target constitutes close to 31 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Integrin alpha-V is a protein encoded by the ITGAV gene. Alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin regulate angiogenesis and cancer progression.

The report 'Integrin Alpha V-Pipeline Review, H2 2018' outlays comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 6 and 18 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively.

Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Respiratory, Infectious Disease, Cardiovascular and Immunology which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Persistent Corneal Epithelial Defects, Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Liver Fibrosis, Metastatic Melanoma, Pancreatic Cancer, Wounds, Age Related Macular Degeneration, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Foot Ulcers, Diabetic Macular Edema, Genital Warts (Condylomata Acuminata), Malabsorption Syndrome, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Rheumatoid Arthritis, Sepsis and Venous Leg Ulcers (Crural Ulcer).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

- The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Overview

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Companies Involved in Therapeutics Development

Biogen Inc

BioMAS Ltd

BrightGene Bio-Medical Technology Co Ltd

Factor Therapeutics Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Morphic Therapeutic Inc

Pliant Therapeutics Inc

SciFluor Life Sciences LLC

Tasly Pharmaceutical Group Co Ltd

Vascular Pharmaceuticals Inc

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Drug Profiles

264-RAD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abituzumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Integrin Inhibit Alpha V and Beta 6 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAT-2094-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BG-00011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGC-0222-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-16Y-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cilengitide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CWHM-12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize Integrin Alpha V Beta 3 and Integrin Alpha 5 Beta 1 for Rheumatoid Arthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-0429-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSP-68-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOD-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCU-200-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Metastatic Melanoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLN-74809-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proagio-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSF-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-0166-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ITGAV and ITGB1 for Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ITGAV and ITGB6 for Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha V for Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha V for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetraiodothyroacetic acid-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-003-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-2690B-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Dormant Products

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Discontinued Products

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)-Product Development Milestones

Featured News & Press Releases

Oct 09, 2018: Merck KGaA to announce data of Abituzumab at ESMO 2018 Congress

Oct 04, 2018: Factor Therapeutics announce treatment completion marks milestone in Phase 2 clinical trial

Oct 02, 2018: Factor Therapeutics provides shareholder update Q3 2018

Sep 05, 2018: Factor Therapeutics announced phase 2 clinical trial for venous leg ulcers nears completion

Aug 06, 2018: Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis

Jul 19, 2018: Cassiopea announces top line positive proof of concept phase II results for CB-06-02 immune modulator in treating genital warts

Jul 16, 2018: Factor Therapeutics: Recruitment Completed in VF00102

Jun 26, 2018: VF00102 CLINICAL TRIAL UPDATE: Screening Closed to New Patients as Recruitment Nears Completion

Jun 14, 2018: Factor Therapeutics: VF001002 Clinical Trial Update

May 14, 2018: Factor Therapeutics announces its VF00102 Clinical Trial Recruitment Enters Final Phase

Apr 10, 2018: Factor Therapeutics Provides Update on VF00102 Clinical Trial

Dec 18, 2017: SciFluor announces positive top-line results of phase 1/2 study of SF0166 eye drops to treat wet age-related macular degeneration

Dec 12, 2017: SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases

Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts

Nov 29, 2017: Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Biogen Inc, H2 2018

Pipeline by BioMAS Ltd, H2 2018

Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2018

Pipeline by Factor Therapeutics Ltd, H2 2018

Pipeline by MedImmune LLC, H2 2018

Pipeline by Merck & Co Inc, H2 2018

Pipeline by Merck KGaA, H2 2018

Pipeline by Morphic Therapeutic Inc, H2 2018

Pipeline by Pliant Therapeutics Inc, H2 2018

Pipeline by SciFluor Life Sciences LLC, H2 2018

Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018

Pipeline by Vascular Pharmaceuticals Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Dormant Products, H2 2018 (Contd..3), H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Therapeutic Products under Development, Key Players in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Therapeutics, Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Pipeline Overview, Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Pipeline, Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Pipeline Assessment


Companies

Biogen Inc

BioMAS Ltd

BrightGene Bio-Medical Technology Co Ltd

Factor Therapeutics Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Morphic Therapeutic Inc

Pliant Therapeutics Inc

SciFluor Life Sciences LLC

Tasly Pharmaceutical Group Co Ltd

Vascular Pharmaceuticals Inc

chat_bubbleLet's Chat